Sanofi (NASDAQ:SNY) Issues Earnings Results, Beats Expectations By $0.05 EPS

Sanofi (NASDAQ:SNY) posted its quarterly earnings results on Thursday. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.88 by $0.05, Zacks reports. Sanofi had a return on equity of 38.98% and a net margin of 9.60%. The firm had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same quarter in the prior year, the firm posted $0.95 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis.

Sanofi Price Performance

Shares of NASDAQ SNY traded down $0.70 during midday trading on Friday, reaching $52.40. 1,994,568 shares of the company traded hands, compared to its average volume of 2,357,098. Sanofi has a 12 month low of $42.63 and a 12 month high of $55.72. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The stock’s 50-day simple moving average is $49.21 and its 200-day simple moving average is $48.69. The firm has a market cap of $132.72 billion, a PE ratio of 26.33, a PEG ratio of 1.63 and a beta of 0.59.

Analyst Ratings Changes

A number of research analysts recently commented on SNY shares. StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Friday. Argus raised their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.